NasdaqCM - Delayed Quote • USD
BioLife Solutions, Inc. (BLFS)
At close: April 25 at 4:00 PM EDT
After hours: April 25 at 4:20 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 6 | 6 | 5 | 4 |
Avg. Estimate | -0.31 | -0.24 | -1.02 | -0.6 |
Low Estimate | -0.41 | -0.34 | -1.28 | -0.69 |
High Estimate | -0.13 | -0.11 | -0.83 | -0.48 |
Year Ago EPS | -0.32 | -0.23 | -1.52 | -1.02 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 8 | 8 | 8 | 6 |
Avg. Estimate | 27.42M | 25.69M | 111.95M | 132.91M |
Low Estimate | 20.9M | 21.9M | 95.79M | 112M |
High Estimate | 33.7M | 35.3M | 146.83M | 173.1M |
Year Ago Sales | 37.7M | 39.51M | 143.27M | 111.95M |
Sales Growth (year/est) | -27.30% | -35.00% | -21.90% | 18.70% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.21 | -0.2 | -0.37 | -0.34 |
EPS Actual | -0.32 | -0.23 | -0.67 | -0.3 |
Difference | -0.11 | -0.03 | -0.3 | 0.04 |
Surprise % | -52.40% | -15.00% | -81.10% | 11.80% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.31 | -0.24 | -1.02 | -0.6 |
7 Days Ago | -0.31 | -0.24 | -1.02 | -0.6 |
30 Days Ago | -0.31 | -0.24 | -1.02 | -0.6 |
60 Days Ago | -0.34 | -0.23 | -0.91 | -0.29 |
90 Days Ago | -0.34 | -0.23 | -0.91 | -0.29 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | BLFS | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 3.10% | -- | -- | 2.60% |
Next Qtr. | -4.30% | -- | -- | 13.40% |
Current Year | 32.90% | -- | -- | 5.20% |
Next Year | 41.20% | -- | -- | 13.30% |
Next 5 Years (per annum) | 10.00% | -- | -- | 11.11% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Initiated | Jefferies: Buy | 4/4/2024 |
Maintains | Craig-Hallum: Buy to Buy | 8/10/2023 |
Maintains | TD Cowen: Outperform to Outperform | 8/9/2023 |
Maintains | Lake Street: Buy to Buy | 8/9/2023 |
Maintains | Stephens & Co.: Overweight to Overweight | 7/17/2023 |
Initiated | Craig-Hallum: Buy | 7/11/2023 |
Related Tickers
AZTA Azenta, Inc.
51.50
-1.13%
ATRC AtriCure, Inc.
22.61
-1.91%
SRT3.DE Sartorius Aktiengesellschaft
282.10
-3.72%
ANIK Anika Therapeutics, Inc.
25.58
-1.24%
EMBC Embecta Corp.
10.40
-4.50%
DIM.PA Sartorius Stedim Biotech S.A.
203.40
-2.35%
NYXH Nyxoah S.A.
11.29
+5.51%
AKYA Akoya Biosciences, Inc.
3.8200
+0.26%
HAE Haemonetics Corporation
87.66
+1.67%
AKP.F Anika Therapeutics, Inc.
24.00
0.00%